Recessive NLRC4-Autoinflammatory Disease Reveals an Ulcerative Colitis Locus

• Published in: Journal of clinical immunology Vol. 42; no. 2; pp. 325 - 335
• Main Authors: Steiner, Annemarie, Reygaerts, Thomas, Pontillo, Alessandra, Ceccherini, Isabella, Moecking, Jonas, Moghaddas, Fiona, Davidson, Sophia, Caroli, Francesco, Grossi, Alice, Castro, Fabio Fernandes Morato, Kalil, Jorge, Gohr, Florian N., Schmidt, Florian I., Bartok, Eva, Zillinger, Thomas, Hartmann, Gunther, Geyer, Matthias, Gattorno, Marco, Mendonça, Leonardo Oliveira, Masters, Seth L.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.02.2022; Springer Nature B.V
• Subjects: Arthralgia; Biomedical and Life Sciences; Biomedicine; Calcium-Binding Proteins - genetics; CARD Signaling Adaptor Proteins - genetics; CARD Signaling Adaptor Proteins - metabolism; Cell activation; Cell lines; Colitis, Ulcerative - diagnosis; Colitis, Ulcerative - genetics; Corticosteroids; Diarrhea; Enterocolitis; Female; Fever; Genome-Wide Association Study; Genomes; Hereditary Autoinflammatory Diseases; Humans; IL-1β; Immunology; Infectious Diseases; Inflammasomes; Inflammasomes - metabolism; Inflammatory bowel disease; Inflammatory bowel diseases; Inflammatory diseases; Interleukin 18; Internal Medicine; Macrophages; Medical Microbiology; Medical treatment; Middle Aged; Mutation; Nucleotide sequence; Original; Original Article; Pathogenicity; Patients; Pyroptosis; Risk factors; Ulcerative colitis; Uveitis; NLRC4-associated autoinflammatory disease; inflammasome; ulcerative colitis
• ISSN: 0271-9142; 1573-2592; 1573-2592
• DOI: 10.1007/s10875-021-01175-4

Purpose NLRC4-associated autoinflammatory disease (NLRC4-AID) is an autosomal dominant condition presenting with a range of clinical manifestations which can include macrophage activation syndrome (MAS) and severe enterocolitis. We now report the first homozygous mutation in NLRC4 (c.478G > A, p.A160T) causing autoinflammatory disease with immune dysregulation and find that heterozygous carriers in the general population are at increased risk of developing ulcerative colitis. Methods Circulating immune cells and inflammatory markers were profiled and historical clinical data interrogated. DNA was extracted and sequenced using standard procedures. Inflammasome activation assays for ASC speck formation, pyroptosis, and IL-1β/IL-18 secretion confirmed pathogenicity of the mutation in vitro. Genome-wide association of NLRC4 (A160T) with ulcerative colitis was examined using data from the IBD exomes portal. Results A 60-year-old Brazilian female patient was evaluated for recurrent episodes of systemic inflammation from six months of age. Episodes were characterized by recurrent low-grade fever, chills, oral ulceration, uveitis, arthralgia, and abdominal pain, followed by diarrhea with mucus and variable skin rash. High doses of corticosteroids were somewhat effective in controlling disease and anti-IL-1β therapy partially controlled symptoms. While on treatment, serum IL-1β and IL-18 levels remained elevated. Genetic investigations identified a homozygous mutation in NLRC4 (A160T), inherited in a recessive fashion. Increased ASC speck formation and IL-1β/IL-18 secretion confirmed pathogenicity when NLRC4 (A160T) was analyzed in human cell lines. This allele is significantly enriched in patients with ulcerative colitis: OR 2.546 (95% 1.778–3.644), P  = 0.01305. Conclusion NLRC4 (A160T) can either cause recessively inherited autoinflammation and immune dysregulation, or function as a heterozygous risk factor for the development of ulcerative colitis.